This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria Group has been evolving with the changing industry dynamics. Given the rising health consciousness and stern government regulations to discourage smoking, this tobacco behemoth has been moving beyond traditional cigarettes and expanding in the smokeless category. We note that revenues from the oral product category have been steadily rising on the back of growing popularity for reduced risk products. In this respect, Altria is gaining from the sale of IQOS in United States, through its licensing deal with Phillip Morris. Further, Altria’s investment in Cronos Group highlights its focus on exploring the cannabis market.
Altria (MO) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $51.61 in the latest trading session, marking a -1.04% move from the prior day.
The Zacks Analyst Blog Highlights: Intel, Altria, Stryker, Sherwin-Williams and Verisk
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intel, Altria, Stryker, Sherwin-Williams and Verisk
Top Stock Reports for Intel, Altria & Stryker
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), Altria (MO) and Stryker (SYK).
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $49.69, moving -1.45% from the previous trading session.
Can Smokeless Unit Help Altria Pare Low Cigarette Sales?
by Zacks Equity Research
Altria (MO) is undertaking efforts to expand in the RRPs space amid receding cigarette shipping volumes.
Big Tobacco Takes a Big Hit (MO) (PM) (BTI) (Revised)
by Zachary Stutler
Since Friday, Altria Group Inc. (MO), Philip Morris International Inc. (PM), and British American Tobacco PLC (BTI) have all fallen 5.1%, 5.9%, and 5.7% respectively as of market close on Wednesday, May 29. And opened Thursday with very little change.
Big Tobacco Takes a Big Hit (MO) (PM) (BTI)
by Zachary Stutler
Since Friday, Altria Group Inc. (MO), Philip Morris International Inc. (PM), and British American Tobacco PLC (BTI) have all fallen 5.1%, 5.9%, and 5.7% respectively as of market close on Wednesday, May 29. And opened Thursday with very little change.
Altria (MO) Up 1.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Altria (MO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Amgen, Altria, Booking, General Motors and Occidental
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Altria, Booking, General Motors and Occidental
Top Stock Reports for Amgen, Altria & Booking Holdings
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), Altria (MO) and Booking Holdings (BKNG).
Buy Marijuana Stocks, Tilray & Aurora Cannabis, Before Earnings?
by Benjamin Rains
The legal marijuana industry is still in the early stages, so let's see if investors should consider buying some pure-play marijuana stocks heading into earnings.
Will Higher Expenses Dent Cronos' (CRON) Earnings in Q1?
by Zacks Equity Research
Apart from the regular top and bottom-line numbers, investors will focus on Cronos' (CRON) pipeline progress, when it reports Q1 results.
Cronos (CRON) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress when the company reports Q1 results.
Company News For Apr 26, 2019
by Zacks Equity Research
Companies In The News Are: TSLA, HSY,UPS,MO
Altria's (MO) Q1 Earnings Miss Estimates, High Interests Hurt
by Zacks Equity Research
Altria's (MO) Q1 performance hurt by high interest expenses as well as lower revenues in the smokeable segment.
FEMSA (FMX) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
FEMSA's (FMX) results for first-quarter 2019 may continue to bear impacts of soft margins and higher costs. However, the company's growth efforts may bring some relief.
Should You Buy Altria (MO) Ahead of Earnings?
by Zacks Equity Research
Altria (MO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can RRPs Lift the Performance of Tobacco Industry Players?
by Vidya Nair
While regulatory hurdles are weighing on cigarette sales, tobacco players are finding some respite in RRPs.
Factors Likely to Shape Colgate's (CL) Q1 Earnings Outcome
by Zacks Equity Research
Colgate's (CL) growth efforts make us confident that it will likely retain the robust bottom-line surprise trend. However, soft margins and adverse currency may be deterrents.
Can Boston Beer (SAM) Beat Q1 Earnings Estimates Despite Odds?
by Zacks Equity Research
Boston Beer's (SAM) first-quarter results are likely to reap benefits of the ongoing strength in shipments and depletions. However, soft Samuel Adams brand performance and higher costs remain woes.
Likely Canopy-Acreage Deal Looks Good Enough to Boost ETF MJ
by Sanghamitra Saha
Canopy Growth will probably purchase the rights to buy Acreage Holdings to tap the growing potential of the U.S. marijuana market. This should bolster the ETF MJ.
Altria (MO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Altria (MO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Pricing & RRPs Aid Altria's (MO) Q1 Earnings Growth?
by Zacks Equity Research
Altria's (MO) Q1 performance is likely to gain from RRPs and high pricing. However, receding cigarette sales are a concern.
Can Coca-Cola (KO) Retain Earnings Trend in Q1 Despite Odds?
by Zacks Equity Research
Coca-Cola (KO) is likely to continue gaining from product launches, and focus on lifting and shifting successful brands globally in first-quarter 2019. However, currency headwinds may hurt results.
5 Consumer Staples Stocks Set to Beat This Earnings Season
by Zacks Equity Research
Although high input costs are a concern for players in the consumer staples sector, a few are likely to gain from prudent acquisitions, savings and brand augmenting efforts.